P1 variant antithrombins Glasgow (393 Arg to His) and Pescara (393 Arg to Pro) have increased heparin affinity and are resistant to catalytic cleavage by elastase. Implications for the heparin activation mechanism.
The heparin affinity of normal and two P1 variants of antithrombin-III (AT) was studied by gradient elution with NaCl in Tris buffer on heparin-Sepharose. At pH 7.4 normal AT eluted at [Na+] 0.78 mol/l and the variants both showed increased affinity with AT Pescara eluting at [Na+] 0.86 mol/l and AT Glasgow at [Na+] 0.92 mol/l. We have earlier proposed a model for heparin activation in which the native state of AT maintains a salt bridge involving the P1 Arg-393 residue. Binding of heparin induces a higher heparin affinity conformation in which the salt bridge is disrupted to reveal the reactive centre for inhibition of thrombin. The Glasgow and Pescara variants, lacking a reactive centre P1 basic residue, would be unable to form this salt bridge, and we suggested that the high affinity conformation which they adopt as their native state would resemble the heparin induced conformation. To examine this model, we measured the heparin induced fluorescence of two P1 variants and tested the susceptibility of their reactive loops to catalytic cleavage. Both variants had fluorescence spectra indistinguishable from normal AT. In the absence of heparin, neither variant was more susceptible than normal to catalytic cleavage by human neutrophil elastase. These findings suggest that the conformation of these P1 variants is different to that of fully heparinized normal AT.
Owen
M C
MC
Department of Clinical Biochemistry, Christchurch Hospital, New Zealand.
George
P M
PM
Lane
D A
DA
Boswell
D R
DR
D000990:Antithrombin III / Q000737:chemistry* / Q000235:genetics; D058833:Antithrombin Proteins; D000991:Antithrombins / Q000737:chemistry* / Q000235:genetics; D002846:Chromatography, Affinity; D004351:Drug Resistance; D014644:Genetic Variation; D006493:Heparin / Q000493:pharmacokinetics*; D006801:Humans; D006868:Hydrolysis; D008958:Models, Molecular; D009504:Neutrophils / Q000187:drug effects / Q000201:enzymology; D010196:Pancreatic Elastase / Q000494:pharmacology*; D011487:Protein Conformation; D013050:Spectrometry, Fluorescence
D058833:Antithrombin Proteins; D000991:Antithrombins; C094336:antithrombin Glasgow; C054089:antithrombin III Glasgow; C059998:antithrombin Pescara; D000990:Antithrombin III; D006493:Heparin; D010196:Pancreatic Elastase